Grandbrothers/iStock Editorial via Getty Images
- The US FDA has issued a Complete Response Letter to Outlook Therapeutics (OTLK) for its resubmitted Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg) for wet age-related macular degeneration.
- Shares are down ~80% in after-hours trading Wednesday.
- The agency said that additional information the company provided
